Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.49) by 32.65 percent. This is a 17.86 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $1.027 million which beat the analyst consensus estimate of $630.000 thousand by 63.02 percent. This is a 67.20 percent increase over sales of $614.243 thousand the same period last year.